Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers

It is believed that pathways of the immune system are responsible for eradicating cancer cells; however, their over-activation and also their ectopic expression in tumor cells and microenvironment are major contributors to tumor growth and chemoresistance. Toll-like receptor 4 (TLR4) pathway is an i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Immunologic research 2019-12, Vol.67 (6), p.505-516
Hauptverfasser:	Kashani, Bahareh, Zandi, Zahra, Karimzadeh, Mohammad Reza, Bashash, Davood, Nasrollahzadeh, Ali, Ghaffari, Seyed H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergology Anticancer properties Antineoplastic Agents - pharmacology Apoptosis Arsenic Arsenic trioxide Biomedical and Life Sciences Biomedicine Breast Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer therapies Cell activation Cell Cycle Checkpoints - drug effects Cell Line, Tumor Chemoresistance Chemotherapy Cisplatin Cisplatin - pharmacology Doxorubicin Drug resistance Drug Synergism Drugs Ectopic expression Female G2 Phase Cell Cycle Checkpoints - drug effects Humans Immune system Immunology Immunosuppressive agents Inflammation Interleukins Internal Medicine MCF-7 Cells Medicine/Public Health Metastases Original Article Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Paclitaxel Paclitaxel - pharmacology Proteins Sulfonamides - pharmacology TLR4 protein Toll-Like Receptor 4 - antagonists & inhibitors Toll-like receptors Tumor cells Tumor Microenvironment - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!